Loading stock data…
MGX
$1.39+0.01 (+0.72%)
Metagenomi Therapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Metagenomi Therapeutics, Inc. in the Healthcare sector is trading at $1.39. The stock is currently near its 52-week low of $1.25, remaining 25.3% below its 200-day moving average. Technical signals show neutral RSI of 49 and bearish MACD signal, explaining why MGX maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 49) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.39
Potential Upside
5%
Whystock Fair Value$1.46
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$53.80M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.57
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-55.40%
Volume
Today's trading volume
127,609
Recent News
Spotlight On 3 ASX Penny Stocks With Market Caps Under A$2B
As Australian shares edge towards a 0.5% advance, buoyed by optimism around geopolitical developments in the Middle East, investors are turning their attention to the potential of penny stocks on the ASX. Although "penny stocks" may seem like an outdated term, they still represent an intriguing investment area for those looking to uncover opportunities in smaller or less-established companies. By focusing on firms with strong financials and growth potential, investors can find promising...
Metagenomi Therapeutics (MGX) Reports Q4 Loss, Misses Revenue Estimates
Metagenomi Therapeutics (MGX) delivered earnings and revenue surprises of -4.35% and -54.84%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Metagenomi Therapeutics: Q4 Earnings Snapshot
EMERYVILLE, Calif. AP) — Metagenomi Therapeutics, Inc. MGX) on Thursday reported a loss of $22.5 million in its fourth quarter.
Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Lag Estimates
Amphastar (AMPH) delivered earnings and revenue surprises of -24.49% and -5.63%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Is Metagenomi Therapeutics (NASDAQ:MGX) In A Good Position To Deliver On Growth Plans?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...